Advanced chondrosarcomas: role of chemotherapy and survival

Italiano, A., Mir, O., Cioffi, A., Palmerini, E., Piperno-Neumann, S., Perrin, C., Chaigneau, L., Penel, N., Duffaud, F., Kurtz, J. E., Collard, O., Bertucci, F., Bompas, E., Le Cesne, A., Maki, R. G., Ray Coquard, I., Blay, J. Y. (November 2013) Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol, 24 (11). pp. 2916-22. ISSN 1569-8041 (Electronic)0923-7534 (Linking)

URL: https://www.ncbi.nlm.nih.gov/pubmed/24099780
DOI: 10.1093/annonc/mdt374

Abstract

BACKGROUND: There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas. METHODS: The medical charts of 180 patients with advanced chondrosarcomas having received chemotherapy in 15 participating institutions between 1988 and 2011 were reviewed. RESULTS: Median age was 52 years. Sixty-three percent of patients had conventional chondrosarcoma and 88% had metastatic disease. Combination chemotherapy was delivered in 98 cases (54.5%). One hundred and thirty-one patients (73%) received an anthracycline-containing regimen. Using RECIST, the objective response rate was significantly different according to histological subtype, being 31% for mesenchymal chondrosarcoma, 20.5% for dedifferentiated chondrosarcoma, 11.5% for conventional chondrosarcoma and 0% for clear-cell chondrosarcoma (P = 0.04). Median progression-free survival (PFS) was 4.7 months [95% confidence interval (CI) 3-6.5]. Performance status (PS) >/=2, number of metastatic sites >/=1 and single-agent regimen were independently associated with poor PFS. Median overall survival (OS) was 18 months (95% CI 14.5-21.6). PS, number of metastatic sites and palliative surgery were independently associated with OS. CONCLUSIONS: Conventional chemotherapy have very limited efficacy in patients with advanced chondrosarcoma, the highest benefit being observed in mesenchymal and dedifferentiated chondrosarcoma. These data should be used as a reference for response and outcome in the assessment of investigational drugs in advanced chondrosarcoma.

Item Type: Paper
Uncontrolled Keywords: Adolescent Adult Aged Aged, 80 and over Anthracyclines/*administration & dosage Antineoplastic Combined Chemotherapy Protocols/*administration & dosage Chondrosarcoma/*drug therapy/mortality/pathology Disease-Free Survival Female Humans Kaplan-Meier Estimate Male Middle Aged Neoplasm Recurrence, Local/*drug therapy/mortality/pathology Neoplasm Staging Prognosis chemotherapy chondrosarcoma treatment
Subjects: diseases & disorders > cancer > drugs and therapies > chemotherapy
diseases & disorders > cancer > drugs and therapies
diseases & disorders > cancer > prognosis
diseases & disorders > cancer > cancer types > sarcoma
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: November 2013
Date Deposited: 20 Oct 2016 16:46
Last Modified: 20 Oct 2016 16:46
PMCID: PMC3811906
Related URLs:
URI: http://repository.cshl.edu/id/eprint/33753

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving